Fair Value Distribution — percentile bands
0.0% of simulations place fair value above current price
WHAT IS PRICED IN
Revenue-Based Reverse DCF
14.9%/yr
±5.7% · revenue growth to justify current price
FCF-Based Reverse DCF
12.9%/yr
±3.0% · FCF growth to justify current price
THE GAP
Market pricing margin expansion or capex normalization
KEY VALUE DRIVERS
Spearman correlation — what moves this valuation most
Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care products in the United States.
No Eagle analysis yet. Request a full review including conviction score, bull/bear cases, and thesis.
No analysis yet
No analysis yet
Kimberly-Clark's 2025 10-K shows transformation in progress. Organic growth of 1.7% is solid but masked by divestitures and FX headwinds. The planned Kenvue acquisition (consumer health) is transforma...